ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,026.57
-1.12%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) Noticias

SGMO Sangamo Therapeutics Inc

0.5101
0.0071 (1.41%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Sangamo Therapeutics Inc SGMO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0071 1.41% 0.5101 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.52 0.503 0.5339 0.5178 0.503
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202415:35BWSangamo Therapeutics to Present Neurology-Focused..
22/3/202407:05BWSangamo Therapeutics Announces Pricing of $24.0 Million..
13/3/202407:05BWSangamo Therapeutics Reports Recent Business Highlights and..
13/3/202407:01BWSangamo Therapeutics Announces Data From Novel Proprietary..
12/3/202417:30BWSangamo Therapeutics Announces Fourth Quarter and Full Year..
27/2/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202407:05BWSangamo Therapeutics Announces U.S. FDA Alignment on..
06/2/202415:35EDGAR2Form 8-K - Current report
05/2/202417:01BWSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study..
26/1/202410:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202416:09EDGAR2Form 8-K - Current report
13/12/202306:55EDGAR2Form 8-K - Current report
28/11/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202315:02EDGAR2Form 8-K - Current report
01/11/202315:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202315:02EDGAR2Form 8-K - Current report
01/11/202315:01BWSangamo Therapeutics Announces Strategic Update and Reports..
25/10/202315:15BWSangamo Therapeutics Announces Third Quarter 2023 Conference..
24/10/202301:01BWSangamo Therapeutics to Present Pre-Clinical Data Showcasing..
20/9/202315:15BWSangamo Therapeutics to Present at the Jefferies Cell &..
29/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202315:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202315:47EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/8/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:08EDGAR2Form 8-K - Current report
08/8/202315:01BWSangamo Therapeutics Reports Recent Business Highlights and..
01/8/202315:15BWSangamo Therapeutics Announces Second Quarter 2023..
20/7/202307:05BWSangamo Therapeutics and Chroma Medicine Announce Option and..
17/7/202307:05BWSangamo Therapeutics Announces Research Evaluation and..
29/6/202307:05BWSangamo Therapeutics and Voyager Therapeutics Enter License..

Su Consulta Reciente

NASDAQ
SGMO
Sangamo Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados